Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 32, Issue 2, 2014, Pages 76-82

  Michaelson, M Dror ^a   Oudard, Stephane ^b   Houede, Nadine ^c   Maurina, Tristan ^d   Ou, Yen Chuan ^e   Sengeløv, Lisa ^f   Daugaard, Gedske ^g   Saad, Fred ^h   Ostler, Peter ⁱ   Jones, Robert ^j   Bahl, Amit ^k   Stenzl, Arnulf ^l   Gschwend, Juergen ^m   Laestadius, Fredrik ⁿ   Ullèn, Anders ⁿ   Castellano, Daniel ^o   Maneval, Edna Chow ^p   Wang, Shaw Ling ^p   Chen, Isan ^p   Lechuga, Maria Jose ^p   Paolini, Jolanda ^p   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSTITUT BERGONIÉ   (France)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g Rigshospitalet   (Denmark)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ MOUNT VERNON HOSPITAL   (United Kingdom)

^j BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^k BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^p PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PLACEBO; PREDNISOLONE; PREDNISONE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TAXOID;

ADULT; AGED; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FOLLOW UP; GLEASON SCORE; HAND FOOT SYNDROME; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; PYRROLES; TAXOIDS; TREATMENT OUTCOME;

EID: 84897018646     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5268     Document Type: Article

References (48)

1. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
2. Tannock IF, de WR, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
3. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
4. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
5. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
6. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
7. Ferrer FA, Miller LJ, Andrawis RI, et al: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329-2333, 1997 (Pubitemid 27208716)
8. Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999 (Pubitemid 29407042)
9. Zeng Y, Opeskin K, Goad J, et al: Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66:9566-9575, 2006 (Pubitemid 44623655)
10. Duque JL, Loughlin KR, Adam RM, et al: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523-527, 1999 (Pubitemid 29407032)
11. Duque JL, Loughlin KR, Adam RM, et al: Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 61:401-408, 2006 (Pubitemid 44639399)
12. Shariat SF, Anwuri VA, Lamb DJ, et al: Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22:1655-1663, 2004 (Pubitemid 41079804)
13. Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 61:2533-2536, 2001 (Pubitemid 32685834)
14. George DJ, Halabi S, Shepard TF, et al: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormonerefractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932-1936, 2001 (Pubitemid 32994827)
15. Chott A, Sun Z, Morganstern D, et al: Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271-1279, 1999 (Pubitemid 29488934)
16. Ko YJ, Small EJ, Kabbinavar F, et al: A multiinstitutional phase II study of SU101, a plateletderived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 7:800-805, 2001 (Pubitemid 32708713)
17. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470, 2003 (Pubitemid 36432420)
18. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
19. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003 (Pubitemid 36109749)
20. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003 (Pubitemid 38019277)
21. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003 (Pubitemid 36857948)
22. Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J Clin Endocrinol Metab 91:4070-4076, 2006 (Pubitemid 44536887)
23. Kodera Y, Katanasaka Y, Kitamura Y, et al: Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13:R66, 2011
24. Dror Michaelson M, Regan MM, Oh WK, et al: Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913-920, 2009
25. Sonpavde G, Periman PO, Bernold D, et al: Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 21:319-324, 2010
26. Oudard SM, Caty M, Rolland F: An open-label phase II study of treatment with sunitinib in patients suffering from metastatic castrated refractory prostate cancer (CRPC) after progression with docetaxel-based regimen. Ann Oncol 21 (suppl 8; abstr 4718), 2010
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
28. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
29. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977
30. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
31. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
32. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012
33. Petrylak DP, Fizazi K, Sternberg CN: A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer: The MAINSAIL trial. Ann Oncol (abstr LBA24), 2012
34. Sanofi and Regeneron announce regulatory and clinical update for Zaltrap (aflibercept; press release). http://en.sanofi.com/Images/30138-20120405- ZALTRAP-BLA-VENICE-en.pdf
35. Steinbild S, Mross K, Frost A, et al: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97:1480-1485, 2007 (Pubitemid 350175850)
36. Chi KN, Ellard SL, Hotte SJ, et al: A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19:746-751, 2008 (Pubitemid 351461047)
37. Ragon-Ching JB, Jain L, Gulley JL, et al: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 103:1636-1640, 2009
38. Pili R, Haggman M, Stadler WM, et al: Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29:4022-4028, 2011
39. Armstrong AJ, Haggman M, Stadler WM: Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of longterm follow-up of a randomized phase II placebo-controlled trial. J Clin Oncol 30 (suppl; abstr 4550), 2012
40. Adamo V, Noto L, Franchina T, et al: Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 3:73, 2012
41. Hussain M, Smith MR, Sweeney C: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 29 (suppl; abstr 4516), 2011
42. Saylor PJ, Mahmood U, Kunawudhi A, et al: Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: Analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 53:1670-1675, 2012
43. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
44. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
45. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
46. Raymond E, Dahan L, Raoul J-L, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
47. Ryan CJ, Smith MR, de Bono JS: Interim analysis results of COU-AA-302, a randomized, phase II study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. J Clin Oncol 30 (suppl; abstr LBA4518), 2012
48. Parker C, Heinrich D, O'Sullivan JM: Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer with bone metastases. J Clin Oncol 30 (suppl 5; abstr 8), 2012